キナーゼデッドのBRAFと腫瘍性RASは,CRAFを通じて腫瘍の進行を促すために協力します
Sonja J Heidorn1, Carla Milagre, Steven Whittaker
1The Institute of Cancer Research, Signal Transduction Team, Section of Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK.
Cell
|February 10, 2010
まとめ
キナーゼデッドのBRAFと腫瘍性RASは,腫瘍の成長を促すために協力する. BRAF阻害剤は,この経路を活性化させ,患者の反応と副作用を予測するために,治療前に腫瘍の遺伝子型決定の必要性を強調します.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- ガンシグナル伝達 ガンシグナル伝達
背景:
- 腫瘍性RAS変異は,がんの一般的な原動力である.
- BRAFシグナル伝達経路は,細胞増殖と生存において極めて重要です.
- BRAFを阻害する標的療法が,がん治療に使用されています.
研究 の 目的:
- キナーゼデッドのBRAFと腫瘍性RASを含む腫瘍発生の新たなメカニズムを解明する.
- 腫瘍性RASの文脈におけるBRAF選択性阻害剤の効果を調査する.
- 臨床実務と患者層分化への影響を理解する.
主な方法:
- タンパク質の相互作用とシグナル伝達を評価するためのインビトロキナーゼアッセイ.
- MEK-ERK経路の活性化を測定するための細胞ベースの測定法.
- メラノーマのインビヴォマウスモデルで腫瘍発生を研究する.
主要な成果:
- キナーゼデッドのBRAFは,腫瘍性RASの存在下では,腫瘍発生を促進する.
- BRAF選択性阻害剤は,RAS依存のBRAFをCRAFに結合させ,MEK-ERK経路を活性化させます.
- この経路の活性化は,腫瘍性BRAF阻害では起こらない.
- キナーゼデッドのBRAFと腫瘍性RASは,マウスのメラノーマを誘発するために協力します.
結論:
- 腫瘍の進行におけるBRAF媒介のシグナル伝達の新しいパラダイムが特定されています.
- 経路のシグナル伝達と腫瘍のゲノタイプ化を理解することは,効果的なBRAF標的治療に不可欠です.
- ゲノタイプ化により,BRAF阻害剤に反応する可能性のある患者,および副作用のリスクのある患者を特定することができます.
関連する概念動画
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity: